Abstract. Objective: To assess the concordance of selfobtained vaginal swabs (SVS), first void urine samples (FVU) and provider-collected endocervical swabs (PES) for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) in adolescents.
Introduction
Adolescent females have the highest rates of chlamydia trachomatis (CT) and neisseria gonorrhea (NG) among all age groups in America (CDC Sexually Transmitted Diseases Surveillance 2005). Since most of the infected adolescent women are asymptomatic, successful detection of CT and NG infections relies on effective, convenient, non-invasive, and low cost diagnostic methods for broad screening. Several previous studies demonstrated that non-invasive alternatives to the traditional endocervical swab, such as urine and vaginal samples to detect reproductive tract infections, are required and well accepted among adolescents. 1e3 The nucleic acid amplification test (NAAT) became available in the last decade for use in clinical microbiology laboratories and has been considered the most sensitive and promising test in identifying CT and NG organisms. The ability to detect CT and NG using urine and vaginal specimens without a pelvic examination is a key advantage of nucleic acid amplification test, and this ability facilitates screening females in situations other than traditional venues. However, given the current limited FDA approval Funded by NICHD RO1 HD37785-04.
for self-collected vaginal swabs (SVS) to health care settings only, it is necessary to demonstrate the equivalent performance of SVS to other specimen types in order to support the expanded CT and NG screening using SVS. This is especially important when screening a high prevalence population.
In this study, we used BDProbeTec ET Ô Amplified DNA Assay (BD Biosciences, Sparks, MD) in detecting CT and NG infections. Although BDProbeTec ET Ô has proved its performance both in men and women, most studies have been limited to adults or mixed age groups. The suitability of tests may vary by the population examined because of acceptability of testing, ability to properly obtain specimens, prevalence of infections and potential endogenous biological variables. The objective of this study was to assess the concordance of two self-collected sampling methods (urine sample and vaginal swab) and conventional provider-collected endocervical sampling (PES) for the detection of CT and NG in adolescent females using BDProbeTec ET Ô .
Materials and Methods

Study Population
Over a period of 5 years from 2001 to 2006, as part of a longitudinal study on hormonal contraceptive use, ectopy, and sexually transmitted infection acquisition, a total of 350 adolescent females were recruited and followed up for the study. This study was carried out at an urban Adolescent Clinic in an academic institution. Healthy female adolescents were eligible to participate if they were 12e18 years old, sexually active, and not currently pregnant or pregnant in the last 3 months. After receiving approval of the institutional review board, written informed consent was obtained from each enrolled adolescent female participant. Study participants completed a computer-assisted sexual behavior questionnaire. A health care provider then completed a detailed medical history and conducted a clinical examination on the adolescent during every 6-month visit. First void urine (FVU), SVS, and PES specimens were collected at baseline and semi-annual follow-up visits.
Specimen Collection and Storage
First void urine: At least one hour since last micturition and prior to swab collection, a urine specimen was collected from each subject into a sterile urine cup, after instructing the patients to collect only up to the 20 ml mark indicated with a black marker. At least 10 ml of urine was poured into a separate urine cup for BDProbeTec ET Ô testing. Self-collected vaginal swab: Prior to the pelvic examination, adolescents were briefly instructed to place a Dacron-tipped swab from the BDProbeTec ET Ô collection devices 1 inch into the distal vagina, rotated 360 and handed back to the provider in the specimen container.
Endocervical swabs: Specimens were collected from each patient as part of the pelvic examination by the clinician using BDProbeTec ET Ô manufacturer-provided collection devices according to package insert.
All specimens were stored in a refrigerator at 2e8 C prior to transfer in an insulated cooler to the main laboratory within 4 days of collection and were processed according to the package insert instructions from the manufacturer.
Amplified DNA Methods
The BDProbeTec ET Ô C trachomatis and N gonorrhea amplified DNA assay was used for the detection of DNA from CT and NG simultaneously. Swabs collected with the BDProbeTec ET Ô specimen collection/transport kit and the portion of the urine sample were tested for C trachomatis and N gonorrhea according to the instructions in the manufacturer's package insert. Results were reported as positive, negative, or indeterminate. Indeterminate results occurred when the CT, NG, and separate amplification control were all negative, indicating inhibition of amplification.
Statistical Analysis
The detection of cervical, vaginal or urethral CT and NG infections by endocervical, vaginal, and urinary sampling was evaluated. A positive result from at least two of the three specimens collected from the same subject at the same study visit was considered true positive. Sensitivity ( 5 true positive/(true positive þ false negative)), specificity ( 5 true negative/ (true negative þ false positive)), positive predictive value (PPV 5 true positive/(true positive þ false positive)) and negative predictive value (NPV 5 true negative/(true negative þ false negative)) were calculated to examine the performance of FVU, SVS and PES in identifying possible infections. Indeterminate results falling into either true positive or true negative category were included in sensitivity, specificity, PPV, and NPV calculations. The kappa statistic (or kappa coefficient) was calculated to evaluate the test agreement between any two of three specimen types. Excellent agreement was defined as a kappa O 0.75. 4 We used SAS 9.1.2 (SAS Institute Inc., Cary, NC, USA) for the data analysis.
Results
Among 350 adolescent females enrolled in the study, 96% were African American, whose median age was 16 (range 12e18) years at their study entry visits. On average, the study participants initiated their sexual activity at 14 (range 10e18) years and had four sexual partners (Table 1) .
Of 350 adolescent female subjects in the study, 342 participants and 1080 baseline and semi-annual visits had BDProbeTec ET Ô test results (including indeterminate results) available for CT and 1079 visits for NG from all three of cervical, vaginal, and urinary samples.
Among the 342 adolescents, the positivity rates for CT and NG were 26.6 and 11.7 per 100 women respectively. Notably, this was a high prevalence population. Of the 1080 visits, 111 visits were tested positive for CT. For NG test, 44 out of 1079 visits were positive based on our true positive standard. Unless mentioned specifically, the following analysis and discussion are based on subject visits.
Sensitivities, specificities, PPV, NPV, and indeterminate results are shown in Table 2 . Overall, selfcollected vaginal specimen was the most sensitive sampling method, followed by endocervical specimen and urine sample, in detection of CT and NG. The specificities and PPV of endocervical swabs in screening both the CT and NG infections were the best, followed by FVU and SVS. For NPV, the PES was again the most accurate sampling method for correctly classifying uninfected cases as negative. However, the SVS yielded the worst PPV for the detection of NG DNA among all three specimen types due to the six false positive results obtained by SVS. In addition, both SVS and FVU generated more false positives than PES, and also the majority of indeterminate results (96%). 'Indeterminate' was reported by the lab indicating the BDProbeTec ET Ô could not determine the status of a sample as positive or negative. In contrast to SVS and FVU, the PES produced the smallest number of false positive and indeterminate results for detecting both CT and NG. This could be the result of less contamination when collecting the endocervical specimen.
The agreement of test results from paired specimens between any two of PES, SVS and FVU and the detailed discrepancy data are showed in Table 3 . It is evident that the overall agreements between specimens were high (from 97% to 99.3%). Nonetheless, there was a consistently better agreement among specimens from three sites for detecting NG than for CT. There were more discrepant results (n 5 32) for CT test between PES and FVU. For NG test, the most discrepant results (n 5 11) were seen between SVS and FVU.
The kappa coefficients were calculated to assess the agreement between paired specimens, as are indicated in Table 3 . The kappa statistic was from 0.83 to 0.89 for the detection of C trachomatis and from 0.87 to 0.91 for N gonorrhea. A kappa greater than 0.75 indicates excellent agreement beyond chance, 0.40 to 0.75 indicates intermediate to good agreement and below 0.40 indicates poor agreement. 4 Thus, kappa coefficients of 0.83 to 0.91 and all lower 95% CIs were above 0.75 in this study, which should be regarded as considerable strength of agreement between specimen pairs for detecting CT and NG infections.
Discussion
The increased sensitivities and specificities of nucleic acid amplification techniques have led to the evaluation of less invasive specimen collection procedures for screening gonococcal and chlamydial urogenital infections. Despite their advantages, there are limitations of NAATs. Of note, the strand displacement amplification test system used by BDProbeTec ET Ô can be inhibited resulting in false negative results. False positive result could also be possible due to specimen contamination. Thus, we were relatively conservative in defining our internal measure of true positive in our analyses, although in the clinical setting we chose to consider even one positive out of three or any amount of specimens as an infection and administer treatment. Nonetheless, this study found strong agreement between self-collected vaginal swabs or urine specimens and provider-collected endocervical swabs in the detection of both CT and NG infections. The performance of self-collected vaginal swabs was at least equivalent to PES or FVU.
A number of studies have reported the correlation among specimens from urine, vagina, and endocervix in detecting CT and NG using various NAATs. In two previous studies using PCR, the sensitivities are over 90% for SVS and more than 70% for FVU; 5 compared with cervical specimens, self-collected specimens have a sensitivity of 100% and a specificity of 93.4% for detection of C trachomatis infection. 6 In a BDProbeTec ET Ô performance study, the sensitivities for CT by PES and FVU are 92.8% and 80.5%; the sensitivities for NG are 96.6% and 84.9%. 7 Compared to these previous studies, this study has shown similar performance of SVS and FVU.
Regarding to the ability to identify CT and NG, our data has demonstrated that excellent performance can be achieved when noninvasive self-obtained vaginal swab specimens are used. Compared to PES, sampling the vagina by the patient is a similar or more sensitive approach for identification of both C trachomatis and N gonorrhea in young women. This finding is consistent with previous studies. 8, 9 In addition to its promising ability to detect CT and NG infection, vaginal swab sampling method has proven to be preferred by women for screening CT and NG. 10e12 Although the sensitivity of urine specimens may be suboptimal compared to SVS and PES, the FVU is the only alternative non-invasive sampling method approved by FDA for collection outside of health care settings. Thus, the FVU sampling methods, along with SVS, can serve as convenient substitutes especially when (1) they are properly chosen to be used for large scale population screening or repeated sampling where the pelvic examination is not suitable due to the cost and time, (2) the cervical screening is refused or cannot be performed or (3) the providers or clinical facilities are not available. Several potential limitations need to be mentioned. Since the purpose of this study was to compare the abilities of sampling three anatomic sites to identify positive result(s) of CT or NG based on a single nucleic acid amplification test, BDProbeTec ET Ô on a one test per specimen basis, we were limited in confirming infection status, even using two positive results as our internal true positive standard. This standard may underestimate the number of ''infected patients'' by disqualifying any single ''infected specimen'' of three specimen types as compared to studies using multiple tests such as culture and/or various NAATs. Therefore, the possibility of misclassification could not be completely avoided. In addition, sensitivity of the BDProbeTec ET Ô Amplified DNA Assay could be decreased if a specimen contained low number of target DNA of targeting pathogen(s), or due to amplification inhibitors. On the other hand, specimen contamination if strict quality control measures are not implemented, or cross-reactivity with genes from related species (particularly for NG), could decrease specificity of the test. Thus, misclassification of a study subject's status in this study could be a result of our true positive definition, specimen collection, process, and/or NAAT. 13, 14 Another limitation was that indeterminate results by all three specimen types were not included in the kappa analysis, which might slightly alter the results of the kappa analysis. Finally, this was a high prevalence study population for both CT and NG. While the agreement and sensitivity was high in this context (high positivity rate population), the generalizability of these results to low prevalence and largely asymptomatic populations may still remain an issue, even when NAATs are being used.
In conclusion, the agreement was excellent among SVS, PES, and FVU in the detection of CT and NG by BDProbeTec ET Ô in our study. Compared to PES and FVU, vaginal sampling performed by the women themselves was the most sensitive approach. The implications of our results are that since the performance of SVS was similar to that of the FDA-approved PES and FVU sampling methods, SVS could be another noninvasive alternative in addition to FVU in screening CT and NG in adolescent females, especially when prevalence is high. In addition, non-invasive SVS and FVU specimen collection will facilitate reproductive tract infection screening among at-risk youth eliminating the need for a clinical speculum examination. Finally, the use of SVS and FVU may be extended to broaden screening in non-clinical settings.
